EUVIMEDEUVIMED entdecken
Crossref

Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors

Hafiza N Saleem, Summara Kousar, Ammar Hassan Jiskani, Iqra Sohail, Amir Faisal, Muhammad Saeed

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202300292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Hafiza N Saleem und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Engineering, SBA School of Science and Engineering, Lahore University of Management Sciences (LUMS), Lahore, Pak…. Hauptthemen laut MEDLINE: Dengue Virus, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Lahore University of Management Sciences, internal faculty initiative funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue fever is a neglected vector‐borne disease and is more prevalent in Asia. Currently, no specific treatment is available. Given the time and cost of de novo drug discovery and development, an alternative option of drug repurposing is becoming an effective tool. We screened a library of 1127 pharmacologically active, metabolically stable, and structurally diverse small anticancer molecules to identify inhibitors of the dengue virus (DENV) NS2B/NS3 protease. Enzyme kinetics and inhibition data revealed four B‐cell lymphoma 2 inhibitors, that is, ABT263, ABT737, AT101, and TW37, as potent inhibitors of DENV NS2B/NS3 protease, with IC 50 values of 0.86, 1.15, 0.81, and 0.89 µM, respectively. Mode of inhibition experiments and computational docking analyses indicated that ABT263 and ABT737 are competitive inhibitors, whereas AT101 and TW37 are noncompetitive inhibitors of the protease. With further evaluation, the identified inhibitors of the DENV NS2B/NS3 protease have the potential to be developed into specific anti‐dengue therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VirusNeoplasmsProtease InhibitorsDrug RepositioningMolecular Docking SimulationStructure-Activity RelationshipPeptide HydrolasesViral Nonstructural ProteinsAntiviral AgentsAniline CompoundsSulfonamidesGossypol

Stichwörter der Autor:innen

NS2B/NS3 proteaseallosteric inhibitorcancer drugcompetitive inhibitorflavivirus/dengue

Substanzen

Protease InhibitorsPeptide HydrolasesViral Nonstructural ProteinsAntiviral AgentsnavitoclaxAniline CompoundsSulfonamidesgossypol acetic acidGossypol

Autor:innen und Institutionen

  • Department of Chemistry and Chemical Engineering, SBA School of Science and Engineering, Lahore University of Management Sciences (LUMS), Lahore, Pakistan.
  • Department of Life Sciences, SBA School of Science and Engineering, Lahore University of Management Sciences (LUMS), Lahore, Pakistan.

Förderung

  • Lahore University of Management Sciences
  • internal faculty initiative funding

Zitieren

APA

Saleem, H. N., Kousar, S., Jiskani, A. H., Sohail, I., Faisal, A., & Saeed, M. (2023). Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300292

Vancouver

Saleem HN, Kousar S, Jiskani AH, Sohail I, Faisal A, Saeed M. Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300292

BibTeX
@article{Saleem2023,
  author = {Saleem, Hafiza N and Kousar, Summara and Jiskani, Ammar Hassan and Sohail, Iqra and Faisal, Amir and Saeed, Muhammad},
  title = {Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202300292}
}
Kostenlos starten →